Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
1. KURA's Phase 2 trial for ziftomenib shows significant complete response rates. 2. The benefit-risk profile of ziftomenib remains highly encouraging. 3. KURA aims for FDA NDA submission in Q2 2025 based on positive trial data. 4. Upcoming Phase 3 trials to start in late 2025 evaluate ziftomenib in AML. 5. KURA's partnership with Kyowa Kirin includes $330 million upfront and potential future milestones.